CIMERLI

Coherus BioSciences Inc🇺🇸 United States

FDA Page

Effective Date: Nov 1, 2022
Approval ID: e0e23118-1490-a554-e053-2995a90ab90c
Products: 2 registered
Version: 9

Regulatory Information

Labeling Type

HUMAN PRESCRIPTION DRUG LABEL

Status

Approved

Full Title

These highlights do not include all the information needed to use CIMERLI safely and effectively. See full prescribing information for CIMERLI. CIMERLI™ (ranibizumab-eqrn) injection, for intravitreal use Initial U.S. Approval: 2022 CIMERLI (ranibizumab-eqrn) is biosimilar with LUCENTIS (ranibizumab injection).

Quick Stats

Total Products2

Labelers2

Label Sections20

Regulatory Agency

🇺🇸

U.S. Food and Drug Administration

United States

Data Sources & Disclaimer: Approval information is sourced from official FDA databases. This content is for informational purposes only and does not constitute medical or regulatory advice. Always refer to official FDA websites for the most current information.